The study discovered a new activity of the autism-linked ADNP in the skin. This activity may serve to define the clinical phenotype of patients with ADNP syndrome. Furthermore, the results suggest CP201 as an attractive medication for skin problems in ADNP patients. This evidence concerns the gene ADNP and autism.